

Catherine King

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5153602/publications.pdf>

Version: 2024-02-01

32
papers

816
citations

471371

17
h-index

501076

28
g-index

33
all docs

33
docs citations

33
times ranked

1371
citing authors

#	ARTICLE	IF	CITATIONS
1	Female reproductive status and exogenous sex hormone use in rheumatoid arthritis patients treated with tocilizumab and csDMARDs. <i>Rheumatology</i> , 2023, 62, 583-595.	0.9	3
2	Precision Medicine With Leflunomide: Consideration of the <i>DHODH</i> Haplotype and Plasma Teriflunomide Concentration and Modification of Outcomes in Patients With Rheumatoid Arthritis. <i>Arthritis Care and Research</i> , 2021, 73, 983-989.	1.5	8
3	A review of liquid biopsy as a tool to assess epigenetic, cfDNA and miRNA variability as methotrexate response predictors in patients with rheumatoid arthritis. <i>Pharmacological Research</i> , 2021, 173, 105887.	3.1	14
4	Association between major depressive disorder and multiple disease outcomes: a phenome-wide Mendelian randomisation study in the UK Biobank. <i>Molecular Psychiatry</i> , 2020, 25, 1469-1476.	4.1	60
5	Mendelian randomization case-control PheWAS in UK Biobank shows evidence of causality for smoking intensity in 28 distinct clinical conditions. <i>EClinicalMedicine</i> , 2020, 26, 100488.	3.2	16
6	Response to interferon-beta treatment in multiple sclerosis patients: a genome-wide association study. <i>Pharmacogenomics Journal</i> , 2017, 17, 312-318.	0.9	28
7	Putting recommendations into practice: Australian rheumatologists' opinions on leflunomide use in rheumatoid arthritis. <i>Clinical Rheumatology</i> , 2017, 36, 791-798.	1.0	2
8	Changes to the Australian Pharmaceutical Benefit Scheme restrictions for biological disease-modifying antirheumatic drugs have influenced the use of leflunomide. <i>International Journal of Rheumatic Diseases</i> , 2017, 20, 1795-1797.	0.9	1
9	Genetic polymorphism of <i>CYP1A2</i> but not total or free teriflunomide concentrations is associated with leflunomide cessation in rheumatoid arthritis. <i>British Journal of Clinical Pharmacology</i> , 2016, 81, 113-123.	1.1	19
10	Semiphysiologically Based Pharmacokinetic Model of Leflunomide Disposition in Rheumatoid Arthritis Patients. <i>CPT: Pharmacometrics and Systems Pharmacology</i> , 2015, 4, 362-371.	1.3	15
11	Lack of Evidence for Genomic Instability in Autistic Children as Measured by the Cytokinesis Block Micronucleus Cytochrome Assay. <i>Autism Research</i> , 2015, 8, 94-104.	2.1	19
12	Pharmacogenomics of NAT2 and ABCG2 influence the toxicity and efficacy of sulphasalazine containing DMARD regimens in early rheumatoid arthritis. <i>Pharmacogenomics Journal</i> , 2014, 14, 350-355.	0.9	25
13	Individualization of leflunomide dosing in rheumatoid arthritis patients. <i>Personalized Medicine</i> , 2014, 11, 449-461.	0.8	6
14	Pharmacogenomics of interferon beta and glatiramer acetate response: A review of the literature. <i>Autoimmunity Reviews</i> , 2014, 13, 178-186.	2.5	52
15	The rheumatoid arthritis susceptibility polymorphism <i>PTPN22</i> C1858T is not associated with leflunomide response or toxicity. <i>Journal of Clinical Pharmacy and Therapeutics</i> , 2014, 39, 555-560.	0.7	7
16	SCN1A variations and response to multiple antiepileptic drugs. <i>Pharmacogenomics Journal</i> , 2014, 14, 385-389.	0.9	20
17	Metabolic and safety issues for multiple sclerosis pharmacotherapy – opportunities for personalised medicine. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2014, 10, 1145-1159.	1.5	3
18	Pharmacokinetic evaluation of teriflunomide for the treatment of multiple sclerosis. <i>Expert Opinion on Drug Metabolism and Toxicology</i> , 2013, 9, 1025-1035.	1.5	40

#	ARTICLE	IF	CITATIONS
19	Identification of Shared Genes and Pathways: A Comparative Study of Multiple Sclerosis Susceptibility, Severity and Response to Interferon Beta Treatment. PLoS ONE, 2013, 8, e57655.	1.1	17
20	Association of <i>DHODH</i> haplotype variants and response to leflunomide treatment in rheumatoid arthritis. Pharmacogenomics, 2012, 13, 1427-1434.	0.6	24
21	The potential role of the antioxidant and detoxification properties of glutathione in autism spectrum disorders: a systematic review and meta-analysis. Nutrition and Metabolism, 2012, 9, 35.	1.3	74
22	Polymorphisms in cytochrome P450 2C19 enzyme and cessation of leflunomide in patients with rheumatoid arthritis. Arthritis Research and Therapy, 2012, 14, R163.	1.6	41
23	Folate and methionine metabolism in autism: a systematic review. American Journal of Clinical Nutrition, 2010, 91, 1598-1620.	2.2	81
24	Genetic polymorphisms, their allele combinations and IFN- β treatment response in Irish multiple sclerosis patients. Pharmacogenomics, 2009, 10, 1177-1186.	0.6	48
25	<i>IL7RA</i> polymorphisms and chronic inflammatory arthropathies. Tissue Antigens, 2009, 74, 429-431.	1.0	38
26	<i>IL7RA</i> Polymorphisms and Susceptibility to Multiple Sclerosis. New England Journal of Medicine, 2008, 358, 753-754.	13.9	32
27	Pharmacogenomics of Type I interferon therapy: A survey of response-modifying genes. Cytokine and Growth Factor Reviews, 2007, 18, 211-222.	3.2	25
28	The MHC2TA δ 168A/G and +1614G/C polymorphisms and risk for multiple sclerosis or chronic inflammatory arthropathies. Tissue Antigens, 2007, 70, 247-251.	1.0	10
29	The neuropeptide genes TAC1, TAC3, TAC4, VIP and PACAP(ADCYAP1), and susceptibility to multiple sclerosis. Journal of Neuroimmunology, 2007, 183, 208-213.	1.1	12
30	CTLA4 gene polymorphisms and multiple sclerosis in Northern Ireland. Journal of Neuroimmunology, 2007, 187, 187-191.	1.1	25
31	ITGA4 polymorphisms and susceptibility to multiple sclerosis. Journal of Neuroimmunology, 2007, 189, 151-157.	1.1	15
32	The CTLA4 +49A/G and CT60 polymorphisms and chronic inflammatory arthropathies in Northern Ireland. Experimental and Molecular Pathology, 2006, 80, 141-146.	0.9	35